According to our new research study on “Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Class, Structures, Indications, and Mode of Action,” the market is expected to grow from US$ 99,021.46 million in 2021 to US$ 257,578.79 million by 2028; it is expected to grow at a CAGR of 15.8% from 2022 to 2028.
The report highlights the key factors driving the market growth and prominent players with their developments in the market. The wide application areas of glycan-based drugs, followed by the development of new treatment processes and increasing research & development in the field of glycomic therapeutics, are the key drivers propelling the market growth. However, the shortage of skilled professionals and lack of research & development laboratories in developing countries is hampering the overall market growth.
Download PDF Sample Copy at:
https://www.theinsightpartners.com/sample/TIPRE00029576/
Glycomics focuses on the structures and functions of complex carbohydrates, as found in glycoproteins, glycolipids, and glycosaminoglycans. Glycans are responsible for much of the structural variation in biologic systems, and their representation on cell surfaces is commonly called the “glycome”. These glycans are present in many areas of the microbiome, including cell surfaces and proteins, and can be incredibly complex. Microbial glycomics is poised to revolutionize disease diagnosis, cancer detection, personalized medicine, antimicrobial vaccine, and drug discovery. As therapeutic agents, glycan-integrated nanomaterials can be used as a vaccine against viral and bacterial infections and cancer cells.
The glycomic therapeutics market majorly consists of the players such as Intellihep Ltd; Protalix Biotherapeutics; BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Halozyme Therapeutics, Inc.; Bayer AG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. The companies have been implementing various strategies that have helped the growth of the company and in turn, have brought about various changes in the market. The companies have utilized strategies such as product launches, expansions, and product upgrades for the growth of their organizations. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Below is the list of the growth strategies done by the players operating in the glycomic therapeutics market:
Aug-2022: Sanofi announced that it has entered into a strategic collaboration with Innovent Biologics. The collaboration aims to accelerate the development of oncology medicines and expand its presence in China.
Have a Call with Analyst:
https://www.theinsightpartners.com/speak-to-analyst/TIPRE00029576/
May-2022: Halozyme Therapeutics announced the completion of its acquisition of Antares Pharma, Inc. The acquisition aims to create specialty products.
June-2022: GSK plc announced an investment of £1bn over ten years to accelerate R&D dedicated to infectious diseases that disproportionately impact lower-income countries. This research will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases (NTDs), and anti-microbial resistance (AMR).
March-2022: Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A. announced final results from the BRIGHT Phase III clinical trial evaluating pegunigalsidase alfa (PRX-102) for the potential treatment of Fabry disease. The results indicate that treatment with 2 mg/kg of PRX-102 administered by intravenous (IV) infusion every four weeks was well tolerated.
Regional Analysis:
By geography, the global glycomic therapeutics market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Buy Report at:
https://www.theinsightpartners.com/buy/TIPRE00029576/
About The Insight Partners:
The Insight Partners is a one top industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Manufacturing and Construction, Technology, Chemicals and Materials.
We offer our clients multiple ways to customize research as per their specific needs and budget.
Contact us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-987